Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
© Miller et al.; licensee BioMed Central Ltd. 2014
Received: 23 December 2013
Accepted: 1 April 2014
Published: 23 April 2014
Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymphoid malignancies are sensitive to GC-driven apoptosis. Resistance to GCs can be a significant clinical problem, however, and correlates with resistance to several other major chemotherapeutic agents.
We analyzed the effect of treatment with the cytosine analogue 5 aza-2’ deoxycytidine (AZA) on GC resistance in two acute lymphoblastic leukemia (T or pre-T ALL) cell lines- CEM and Molt-4- and a (B-cell) myeloma cell line, RPMI 8226. Methods employed included tissue culture, flow cytometry, and assays for clonogenicity, cytosine extension, immunochemical identification of proteins, and gene transactivation. High throughput DNA sequencing was used to confirm DNA methylation status.
Treatment of these cells with AZA resulted in altered DNA methylation and restored GC-evoked apoptosis in all 3 cell lines. In CEM cells the altered epigenetic state resulted in site-specific phosphorylation of the GR, increased GR potency, and GC-driven induction of the GR from promoters that lie in CpG islands. In RPMI 8226 cells, expression of relevant coregulators of GR function was altered. Activation of p38 mitogen-activated protein kinase (MAPK), which is central to a feed-forward mechanism of site-specific GR phosphorylation and ultimately, apoptosis, occurred in all 3 cell lines. These data show that in certain malignant hematologic B- and T-cell types, epigenetically controlled GC resistance can be reversed by cell exposure to a compound that causes DNA demethylation. The results encourage studies of application to in vivo systems, looking towards eventual clinical applications.
Keywords5 Aza-2’ deoxycytidine Apoptosis Dexamethasone Epigenetic Glucocorticoid Glucocorticoid receptor Methylation p38 Phosphorylation Leukemia Lymphoid Myeloma High throughput sequencing CEM Molt-4 RPMI 8226
Malignant cells may preempt the natural epigenetic mechanism of cytosine methylation to alter expression of genes so as to escape anti-cancer therapy. Epigenetics includes chemical modifications of DNA, and/or chromatin structural proteins such as nuclear histones, with resulting effects on gene transcription. Methylation of cytosine nucleotides in genomic CpG islands, often located in proximal promoter regions, is known to negatively affect transcription of certain genes. In cancer, disruption of the normal DNA methylation patterns can result in an aberrant epigenetic state with substantial consequences, such as repression of tumor suppressors, leaving cells susceptible to oncogenetic transformation [1–7]. The cellular epigenetic state can affect other factors as well, e. g. cell cycle arrest through p21WAF1 and activation of the p38 MAPK signal transduction pathway . Expression of nuclear hormone receptors, including the GR, also has been shown to be affected at the epigenetic level [9–11]. Repression of gene expression based on DNA methylation can be reversed by analogs of cytosine such as 5 aza-2’ deoxycytidine (AZA), which incorporate into the genome of actively dividing cells and can render the cytosine nucleotide sites which they replace incapable of methylation [1, 3, 6, 8, 12]. Clinically, AZA alone shows promising activity against acute myeloid leukemia and myelodysplastic syndromes [1, 3, 12, 13].
GC-driven apoptosis of several types of leukemic cells provides the rationale for use of GCs in many chemotherapy regimens. This GC action requires activation of the GR (nr3c1), a ligand-dependent transcription factor, with subsequent regulation of a complex gene network , one affected strongly by other signal transduction pathways, including those involving protein kinase A (PKA) and the mitogen-activated protein kinases (MAPKs) [15–18]. However, GC resistance can be a clinical problem, often associated with resistance to other drugs and poor overall prognosis. Examination of clinical leukemia specimens has revealed that resistance in vivo is occasionally due to mutation within the GR gene or loss of GR, but too often it is found that though the GR is present and unmutated, the receptor is ineffectual in causing apoptosis [19–22].
In 1983, it was discovered that in the mouse spontaneous thymic lymphoma cell line SAK8, the DNA methylation state could affect GC-sensitivity [23, 24]. We subsequently tested AZA on dexamethasone (Dex)-resistant human leukemic CEM cells, producing a few sub-clones of apparent revertants to sensitivity . Based on this preliminary work, we have now tested the hypothesis that apoptotic sensitivity to GCs in certain human hematologic malignancies is controlled via the epigenetic state of the genomic DNA by examining the ability of AZA treatment to restore GC sensitivity to cells from three hematological malignancies: two types of acute lymphoblastic leukemia (ALL), CEM clone C1-15 (preT or early T-cell), and uncloned MOLT-4 (T-cell), and a resistant myeloma cell line, RPMI 8226. We confirm that treatment with AZA can convert GC-resistant CEM cells to GC-sensitive and show that this effect extends as well to the other cell lines, representing both T- and B-lineage malignancies. After AZA treatment, some clones appear stably converted to GC- sensitive. We show that in this conversion, several cell line-specific effects relevant to GR function occur. These include altered GR expression from transcriptional start sites at specific untranslated exons located in CpG islands, hypomethylation, expression and sensitivity to GC of coregulatory factors that affect GR actions, and in the MAPK pathway, alterations known to be favorable for GR phosphorylation and action. Our present study connects the cellular DNA methylation state with the networked, hormone-driven apoptotic actions of the GR. The results encourage research at the in vivo level, and since AZA is already in clinical use for certain hematologic malignancies, our results open the possibility of extending use of demethylating compounds to revert GC resistant malignancies to GC sensitive.
Brief exposure to the genomic DNA demethylating agent AZA restores the GC-dependent apoptotic response in each of three cell lines
CEM cells (Figure 1). Visual and Vi-cell evaluation of the CEM-C1-15 cell clones indicated that no clone in this experiment treated with DMSO alone reverted to GC-mediated apoptotic sensitivity. On the other hand, many clones from AZA-treated C1-15 cells showed high Dex sensitivity. Clone IV B9 (extreme upper right, Figure 1A) derived after AZA, showed a striking reversion to Dex-sensitivity, and it remained phenotypically stable over 4 months in continuous culture and after repeated freeze-thawing; therefore it was taken for further evaluation. Cytosine extension assay results (Figure 1B) indicated that clone IV B9 DNA was 4-fold hypomethylated relative to CEM-C1-15 cells. High throughput DNA sequencing showed regions of reduced methylation in DNA in all autosomes, relative to the resistant CEM C1-15 cells. From CEM C1-15, CEM C7-14 and revertant IV B9 cells, non-methylated and methylated DNA were separated and sequenced (Methods). The average coverages for non-overlapping 5,000 bp windows were calculated across all chromosomes, examining all DNA and also only unique gene locations. Coverage comparisons of C1-15 and C7-14 sequences enriched for methylated DNA showed that many C1-15 sequences contained regions- both repeat sequences and unique sequences- with high methylation that were not found in the C7-14 data. Similarly, a plot of sensitive revertant IV B9 against its resistant parent C1-15 revealed loss of methylation at many sites in IV B9.
Figure 1 D, CEM clones
Figure 2 D, MOLT- 4 (uncloned)
AZA + Dex
Figure 3 D, RPMI (uncloned)
RPMI clone II E6
MOLT-4 cells. Of the 3 cell systems, MOLT-4 showed the greatest acute response as a mass culture (Figure 2 and data cited in text). Clearly, there also is a shift to more GC response in the demethylated clones from MOLT-4 cells (Figure 2A). Upon extended culture, the Dex-sensitive phenotype of these clones proved to be unstable, however. The data in Figure 2B-2D therefore evaluate the Molt-4 mass culture following acute treatment with AZA and Dex. Test of the DNA after 48 hours of exposure to AZA confirmed demethylation (Figure 2B). Treatment of the cells with AZA for 24 hours followed by the addition of Dex resulted in a marked loss of cell viability over time (Figure 2C). After treatment with AZA only, there was a 20-25% reduction in viable cells (% culture viability, y-axis) Dex alone reduced viability by only about 5%. AZA followed by Dex, however, reduced viability in this experiment by 50%. These results support the conclusion that an epigenetic state is responsible, at least in part, for the GC resistance of many Molt-4 cells, though the AZA/Dex synergy could include additional mechanisms. Flow cytometry also indicated that the mass culture of MOLT-4 cells treated with AZA had undergone some cell loss (Figure 2D lower left panel and Table 1) However, there was a drastic reduction of intact cells after treatment with AZA followed by Dex, and an increase of cell debris, coupled with a reduction in total viable cells, resulting in a reduction in cells available for evaluation by flow cytometry. (Figure 2D, lower right panel. The scale for all histograms in Figure 2D is identical.) The cytometric evaluation also showed a shift of the residual population into G1, typical of the apoptotic effect of Dex in many lymphoid cell systems, e.g. CEM . Since phase-contrast microscopy had shown these cells to go through the morphologic phases of apoptosis, we conclude that at this 96 hr time point, many cells in the culture had gone on to secondary necrosis/lysis.
RPMI cells (Figure 3) The mass culture of RPMI 8226 myeloma cells also became sensitive to Dex-induced lysis after treatment with AZA. Many outgrown clones showed significant growth arrest and ongoing apoptosis (Figure 3A). The most sensitive clone (II E6) was stable in phenotype and was kept for further analysis. In this clone, cytosine extension assay did not detect a statistically significant shift in total DNA methylation (Figure 3B). Exposure of clone II E6 to Dex revealed a significant loss of viable cells by 48 hr, comparable to CEM clone IV B9, and faster than CEM clones C1-6 and C7-14 (Compare Figures 1C and 3C). Flow cytometry also showed that under control conditions, clone II E6 sustained an ongoing low level of apoptosis, presumably a result of the earlier AZA treatment (lower left panel, Figure 3D and Table 1) After 96 hr in Dex, clone II E6 showed a near complete loss of viable cells, and only a few remaining cells had sub-diploid DNA content (Figure 3D Note, the scale of the Y-axis in all panels of 3D is identical, and see Table 1).
Clonogenicity is lost in RPMI 8226 cells treated with AZA and Dex
Clonogenicity of RPMI 8226 cells
(% wells w viable cells)
(×10-5) ± SD
6.0 ± 1.3
0.15 ± 0.3
6.9 ± 1.3
1.2 ± 1.5
0.7 ± 0.6
0.06 ± 0,1
AZA + Dex
0.14 ± 0.1
The data of Figures 1 , 2 and 3 and Tables 1 and 2 demonstrate that in three cell systems, AZA treatment restores sensitivity to Dex-induced cell death. In an initial exploration of mechanisms, we examined the effects of the AZA treatment on some known important elements in Dex-dependent apoptotic pathways.
GC-stimulated events involving p38 MAPK , a feed- forward stimulator of GR action, are important for glucocorticoid-dependent apoptosis in all 3 cell systems
GR functions are enhanced by differing mechanisms in CEM and RPMI 8226 cells
RPMI 8226 myeloma cells: The GC-sensitive revertant II E6 has altered expression of several genes known to affect GR-driven transcription
The central finding of the research reported here is that treatment of three different lymphoid cell lines with AZA converted the cells from glucocorticoid-resistant to glucocorticoid-sensitive. The data show that the GC Dex, given to each resistant cell system soon after AZA, caused the death of the large majority of cells in the cultures (Data in Results text and Figures 1, 2 and 3). Consequent important issues are, what is the nature of the cell death and by what mechanisms is it achieved? As to the nature of the cell death, both the knowledge that GCs cause lymphoid cell apoptosis and our data herein suggest that at least the major death pathway in the AZA, then Dex-treated cells is indeed apoptosis. The original discovery of apoptosis was made by histopathology [40, 41], and indeed, lymphoid cells are one of the classic systems used to describe the phenomenon . Following the recommendations of a large panel of cell death experts , we employed several methods for evaluating the process- phase contrast microscopy, dye exclusion, cell shrinkage, and cell cycle analysis- and the results all point to apoptosis. It may be useful in the future for ourselves or others to examine additional elements of apoptosis pathways, of interest to particular labs.
As to mechanism, the first question is whether altered DNA methylation is involved. AZA is well-known to cause reversal of DNA methylation, but the drug can also have other effects. We strongly suspect that a major reason for the restoration to GC sensitivity is altered expression of genes suppressed by DNA methylation in the resistant cells, but we cannot rule out the possibility that some of the restored sensitivity in the short-term is due to a combination of GC and other AZA effects. These seem much less likely in long-term revertant cell clones. In our previous work, comparisons of gene expression between Dex-sensitive clone CEM-C7-14, Dex-resistant CEM-C1-15, and the spontaneous resistant-to-sensitive revertant CEM-C1-6  had suggested that GC-resistance in CEM cells could be due to altered regulation of large gene networks, a result consistent with epigenetic control. That is, the extent and pattern of gene expression in the resistant cells and their sister sensitive cells seemed too broadly different to be due to mutation of a single gene . Also, our previous preliminary results on the role of DNA methylation in regulating GC-driven apoptosis supported this interpretation . Consequently, we tested the hypothesis that DNA methylation of hematological cells could result in loss of the GC-sensitive phenotype. We treated with AZA to try to alter the methylation state of 3 cell systems from different GR-positive, GC-resistant human hematological malignancies: acute lymphoblastic leukemias Molt-4 (T-cell), and CEM clone C1-15 (CD4+/CD8+) and the multiple myeloma (B-cell) line RPMI 8226. (CEM cells have been designated as either T or pre-T, because they express surface antigens for both CD4 and CD8, with CD4 predominating quantitatively). Exposure of these B- and T-lineage lines to AZA results in sensitization of their mass cultures to Dex-evoked apoptosis, measured by Dex-dependent: reduction of viable cells, increased apoptotic, still intact cells, followed by eventual cell lysis, and by loss of clonogenicity. We therefore conclude that most of the cell death seen in the revertant cells is apoptotic, given the known pro-apoptotic effects of GCs in lymphoid cells. Total cell DNA methylation was reduced in the CEM and MOLT-4 cells, but not in the revertant RPMI clone. Of course, a reduction in overall methylation is by no means necessary for demethylation at critical sites to have taken place. Considering that these cells had gone through many divisions, and the known demethylating effect of AZA, we conclude that our data best support the interpretation that apoptotic sensitivity to GCs in cells from certain lymphoid malignancies can be controlled by the epigenetic state of the DNA, as our previous work suggested. We note that epigenetic control of GC sensitivity at the histone methylation level has also been reported [19, 43]. The importance of epigenetic regulation in hematologic malignancies is well documented, and efforts are being made to to manipulate such regulation in vivo [44–51]. Therapy with AZA-like drugs directed at myelodisplastic syndrome and AML has given promising results.
As to the mechanisms responsible for the switch to GC sensitivity, and considering the complex regulatory networks that control cell health and death and the widespread alterations in DNA methylation, no doubt multiple systems will have been affected. We therefore made choices as to initial studies of mechanism. Because the reversal of phenotype proved to be unstable in MOLT-4 clones, we limited experiments to comparing the effects of AZA, Dex and AZA followed by Dex on the mass cultures (Figure 2 and Results, text). While this limits detailed studies of the detailed pathway mechanisms, due to population heterogeneity, it does allow examination of the effects of each treatment on the system. The data show that AZA alone had an acute toxic effect, Dex alone had little, and the sequential combination was much more effective in causing cell death. Stable clones could be obtained from the CEM and RPMI cells. We elected to pick the most clearly sensitive of these for more detailed work-up. While one cannot expect to discover the mechanisms that occur in every cell or in vivo from such studies, one can hope to find pathways of importance. Such an approach has proven valuable innumerable times in the history of science. As a first, obvious system to investigate, we explored the GR and several systems that control its actions in AZA-treated, stable clones from the CEM and RPMI cells. The known apoptotic effects of GCs in lymphoid cells require adequate levels of functional GR. We document several processes that enhance the activity of the GR, in a cell-line specific manner. In the stably sensitized clone of CEM cells, we noted restoration of several relevant GR properties to levels found in GC-sensitive cells: transcription from important GR promoter sites; GC-mediated GR induction; and site-specific phosphorylation of the GR, coupled with an increase in its transcription-factor potency.
In the RPMI 8226 system, reversion to GC sensitivity did not correlate with increased GR autoinduction or quantity. Instead, it correlated with alterations in expression of GR co-regulators c-Myb, PGC-1a and PU.1 in ways that, according to published reports of their actions [38, 39, 52], should enhance GR activity. Detailed follow-up of this result will require experiments beyond the scope of this paper.
Common to all three model cell systems was activation of p38 MAPK; a kinase that phosphorylates and thus activates the GR and is important for GC-driven apoptosis of several types of malignant lymphoid cells . We showed that the balance between MAP kinases JNK, ERK and p38 is one determinant of GC sensitivity . This relationship was shown to be important for GC sensitivity in 8 unrelated hematologic cell lines . We hope that these initial findings as to mechanism will lead to experiments in other lymphoid systems, and that the results herein will have applicability beyond the cell lines we tested.
Our results may have potential for eventual clinical relevance. GCs are used widely in the treatment of lymphoid malignancies, due to GC-dependent apoptosis of the malignant cells. But resistance can occur, and resistance to GC often correlates with resistance to other chemotherapeutic drugs. Though simple loss of GR has been documented in lymphoblasts from late-stage resistant ALL, and from some lymphomas, this mechanism does not seem to explain the majority of clinical resistance to GCs [20, 21, 53]. That the GR is required for GC-driven apoptosis, however, seems quite clear. The GR is one hub of a complex set of interactive networks that include at least: c-myc, the MAPKs, PKA, polyamines, and redox pathways [31, 32, 40, 54–58]. Thus it is encouraging that despite this complexity, treatment with AZA resulted in sensitization to GC-induced apoptosis of 3 differing lymphoid cell lines. Thus, the data presented herein provide encouragement for additional studies aimed at eventually translating DNA demethylation to clinical use in lymphoid malignancies, as a means of producing/enhancing sensitivity to GC.
Short-term treatment with AZA produced acute- and in some clones, prolonged sensitivity to GC-driven apoptosis in 3 lines of malignant lymphoid cells (2 T cell or pre-T and one of B cell lineage).
One nodal function seen to be altered in all three systems was the activation of p38 MAPK, a known GR-driven forward feedback system important for eventual lymphoid cell apoptosis.
Further mechanisms were cell-line specific and included alteration in use of GR promoters, GC-driven induction of the receptor, and altered regulation of cofactors that modulate GR function.
Given the successful use of DNA demethylating agents in vivo for the treatment of certain malignancies, these results encourage further trials of such agents to restore/enhance GC sensitivity in lymphoid malignancies.
Unless stated otherwise all chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture and treatment
CEM cell clones were derived from the original cell line CEM-CCRF, which was developed from cells of a pediatric patient with T-cell ALL. CEM-C1-15 is a Dex-resistant sub-clone obtained without selective pressure from its parental resistant clone, CEM-C1. CEM-C1-6 is a spontaneous revertant to sensitive from CEM-C1 . Clones CEM-IV B9 and RPMI II E6 were chosen from a subpopulation of CEM-C1-15 or RPMI 8226 cells treated with AZA. CEM-C7-14 is a subclone of CEM-C7; both are naturally Dex-sensitive. Molt-4 and RPMI 8226 cells were from the American Type Tissue Collection (ATCC, Manassas, VA). CEM cells were grown in RPMI 1640 (Cellgro, Mediatech Inc. Herndon, VA) supplemented with 5% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA). Both Molt-4 and RPMI 8226 cells were propagated in RPMI 1640 supplemented with 10% FBS, 10 mM Hepes buffer (Cellgro), and 1 mM sodium pyruvate. All cells were grown in a tissue culture incubator in a humidified atmosphere at 37°C, 95% air / 5% CO2 and subcultured regularly to ensure logarithmic growth. To evaluate Dex sensitivity, cells were treated with either ethanol vehicle (control) or concentrations of Dex ranging from 1 nM to 4 μM. For experiments examining the contribution of p38 MAPK, cells were pre-treated for 1 hour with DMSO vehicle or 1 μg/ml SB (p38 inhibitor) for CEM cells or 2 μg/ml SB for Molt-4 and RPMI 8226 cells before adding 1 μM Dex. Cells were enumerated and sized, with viability determined by Trypan blue exclusion assay, using a Vi-cell automated counter (Beckman Coulter, Fullerton, CA). For evaluation of acute demethylation, Molt-4 cells were exposed to 100 nM AZA for 24 hours prior to adding 1 μM Dex.
Derivation of clones and analysis of Dex sensitivityciv
Preliminary dose-response experiments established the optimal concentration of AZA for production of Dex sensitivity. Consequently, CEM-C1-15, Molt-4, or RPMI 8226 cells were incubated for 48 hours in 100 nM AZA or an equal volume of its DMSO vehicle for controls, after which time the cells were pelleted by centrifugation (Beckman Coulter, Allegra 6R table-top centrifuge) at 200 × g for 5 minutes at room temperature, their supernatant medium aspirated, and resuspended in 10 mls of sterile phosphate-buffered saline (PBS) (Cellgro). Cells were pelleted as before, resuspended in fresh growth medium without AZA, and allowed to recover for 5 days. The samples were cloned by serial dilution to single cells in RPMI 1640 supplemented with 10% FBS and an insulin-transferin-selenium supplement cocktail. Cloning medium for Molt-4 and RPMI cells also contained 10 mM Hepes and 1 mM sodium pyruvate. Approximately 1 month after cloning, cell populations from each clone were grown to about 105 cells per ml and evaluated for Dex sensitivity by exposure ± 1 μM Dex for 96 hours. At that time, cells were counted and evaluated for Trypan Blue dye exclusion, size and morphology (Vi-cell, Beckman). Two calculations were performed: 1.% apoptosis in the residual whole-cell population = % Trypan Blue positive cells in Dex-treated population munus % TB positive cells in Vehicle-treated Control population; and 2. “growth represson” = (100-% Trypan Blue neg cells/total cells, Dex/Control).
Analysis of cell death
The Guidelines published in 2009 in Cell Death and Differentiation were followed: “…investigators need to combine at least two distinct methods,…and perform, whenever possible, long-term survival assays…” . Accordingly, cells were evaluated in 4 ways- by phase contrast light microscopy, by vital dye exclusion and cell size- with on-screen visualization of cultures (Vi-cell, Beckman), by flow cytometry, and by multiday cell cultures following total and viable cells over time.
RPMI 8226 cells were incubated with 100 nM AZA or DMSO vehicle for 40 hours before addition of ethanol vehicle or 1 μM Dex for an additional 96 hours. Cells were then counted and immediately serially diluted in multi-well dishes to initial average densities of 1000, 100, 10, or single cells per well. After 2 weeks they were evaluated by Trypan blue exclusion assay for wells with live cells and viable cells per well enumerated.
Cytosine extension assay
The methylation state of cytosines within genomic DNA was analyzed using a cytosine extension method . Cellular genomic DNA was extracted from logarithmically growing CEM-C1-15, CEM-IV B9, RPMI 8226, RPMI-II E6, or Molt-4 cells treated with DMSO vehicle or 100 nM AZA for 48 hours using a Qiagen DNeasy mini-prep kit (Qiagen, Valencia, CA). Residual RNA contamination was eliminated by digestion with 400 μg of RNase A. Purified DNA was quantified and 2 μg was digested overnight at 37°C using 8 units of the methylation-sensitive restriction enzyme Hpa II (New England Biolabs, Ipswich, MA). Extension was performed by combining 0.25 μg of digested DNA in the presence of 3H deoxycytidine triphosphate (dCTP) (53.0 Ci/mmol, Perkin Elmer, Waltham, MA), 0.25 units of TAQ polymerase (New England Biolabs), and buffer supplied with the enzyme for 1 hour at 56°C. Samples were subsequently placed on ice and duplicate 10 μl aliquots were bound onto Whatman DE-81 ion exchange filter papers (Whatman Inc., Florham Park, NJ) using a vacuum manifold. Filters were washed 3 times with 0.5 ml room temperature PBS, air dried, submerged in 3 mls of Scintiverse scintillation fluid (Fisher Scientific, Fair Lawn, NJ), vigorously vortex mixed for 15 seconds, allowed to recover for 1 hour, and evaluated using a Beckman scintillation counter (Beckman Coulter).
Propidium iodide staining and flow cytometry
CEM-C7-14, CEM-C1-6, CEM-C1-15, CEM-IV B9, RPMI 8226, and RPMI-II E6 cells were diluted to a starting density of 5×104 viable cells/ml and treated with ethanol vehicle (control) or 1 μM Dex for 96 hours. Molt-4 cells were diluted to 5×104 viable cells/ml and treated with ethanol/DMSO vehicle (control), 1 μM Dex alone, or pre-treated for 24 hours with 100 nM AZA after which time 1 μM Dex or ethanol vehicle was added for an additional 72 hours. Cell nuclear suspensions were prepared, stained by PI, and analyzed by flow cytometry in the UTMB Cytometry Core Lab as described .
Quantitative, real-time PCR of mRNA transcripts
TaqMan® real-time PCR assay and Taqman One-Step RT-PCR reagents (Applied Biosystems, Foster City, CA) were used to detect mRNA transcripts. The primers and Taqman probes used for hGR transcripts (1A3, 1C and 1D), c-Myb and PU.1 were described previously . For measuring PGC-1a mRNA transcripts, 5′-AGAGACAAATGCACCTCCAAAAA-3′ (forward), 5′-6-FAM-AAGTCCCACACACAGTCGCAGTCACAA-TAMRA-3′ (Taqman probe) and 5′-AAAGTTGTTGGTTTGGCTTGTAAGT -3′ (reverse) were synthesized (Integrated DNA Technologies, Inc., San Diego, CA). The RT-qPCR reactions were measured on an ABI Prism 7900H Sequence Detection system (Applied Biosystems) and the results were normalized by endogenous 18S rRNA of each sample. The experiment was repeated and the results were pooled for statistical significance analysis (paired-sample t-test). Less than 5% (p < 0.05) of possible difference was considered significant.
Logarithmically growing CEM-C7-14, CEM-C1-6, CEM-C1-15, and CEM-IV B9 cells were diluted to a starting density of 4×105 viable cells/ml and treated for 16 hours with 100 nM Dex (GR blot), 1 μM Dex (p38 blot), or ethanol/DMSO vehicle (control). Evaluation of GR phospho-S211, total GR, phospho-p38, total p38, and actin by immunoblot was carried out as previously described [17, 18].
GR transactivation assay
Logarithmically growing CEM-C1-6, CEM-C1-15, or CEM-IV B9 cells were collected by centrifugation, washed with 10 ml of sterile 37°C PBS and recollected. The cells were resuspended to a density of 1×107 viable cells/ml in serum-free 37°C RPMI 1640 containing 1.25% DMSO. Aliquots (400 μl) of the suspension were placed into 0.4 cm gap electroporation cuvettes (Bio-Rad, Hercules, CA) containing 15 μg of GRE-dependant mouse mammary tumor virus (MMTV) luciferase reporter vector phh-Luc (ATCC) prepared using a Qiagen maxi-prep kit (Qiagen). Cuvettes were electroporated using 975 μF and 270 V with a Gene Pulser II (Bio-Rad). Electroporated cells were diluted in 4 ml (per cuvette) of RPMI 1640 supplemented with 5% FBS and 1.25% DMSO and recultured. Twenty-four hours after electroporation, cellular debris was removed by filtering through a 70 μm nylon cell strainer (BD Biosciences (Falcon), Two Oak Park, Bedford, MA) and cells were pelleted, resuspended in fresh RPMI 1640 containing 5% FBS, and viable cells were quantified by hemacytometer using Trypan blue exclusion. The cultures were diluted to 2.5×105 viable cells/ml in RPMI 1640 supplemented with 5% FBS, treated with ethanol vehicle (control) or 1 μM Dex, divided into 500 μl triplicate aliquots for each treatment, and placed in a 48-well tissue culture plate (Costar, Cambridge, MA). Twenty-four hours after Dex treatment, cells were pelleted and washed with PBS. Luciferase activity was evaluated by lysing cell pellets in reporter lysis buffer (Promega, Madison, WI), 1 round of freeze-thaw at -80°C to 37°C, and activation of enzymatic activity using luciferase substrate (Promega). Relative light units (RLU) were read using a Monolight luminometer (BD Biosciences). RLUs were normalized to μg of protein in the cellular lysate through use of a BCA protein assay (Pierce, Rockford, IL).
High Throughput DNA sequencing
Total DNA from cells of C1-15, C7-14, and post-demethylation clone C1-15 IV B9 was fragmented by sonication into pieces of about 200 bp. DNA preparations were obtained representing DNA enriched for non-methylated or methylated by an immunoprecipitation procedure according to manufacturer’s protocols. . These fractions were sequenced in 36 bp fragments (reads) using an Illumina GA IIx instrument, following the manufacturer’s protocols. Quality assessment, trimming, and filtration of low quality reads were performed using our Slim-Filter software application . The resulting high quality 31 bp reads were mapped to the reference human genome, build 37.3, using our in-house software. The ratios of experimental to theoretical reads at each position were computed to “normalize” the results, allowing comparisons of samples. The relative methylation status of all autosomes was determined, and the coverage across the chromosomes was calculated using a non-overlapping window size of 5000 bp. The raw sequencing data have been deposited as FASTQ files in SRA data base, identifiable under PRJNA209577. For more specific data, please contact the Corresponding Author.
Primers for amplification of GR proximal promoters
EBT has over 50 years’ experience in the use of cell lines to study GC actions and their applications to clinical situations. AM is experienced in cell culture, molecular biology and biochemistry techniques. WV has intensively studied the use of GR promoters for many years; CG, now an independent molecular biologist, studied and worked under WV’s direction. YF is a leader in next-gen DNA sequencing; under his direction GG, MS carried out the relevant experiments. WW, an expert in application of next-gen sequencing to mitochondria, helped analyze the GR promoter data. LS is an expert in the chemistry and biology of DNA damage; JY is an expert in pyrosequencing, in the LS lab.
5 aza-2’ deoxycytidine
Activation function 1 domain of the glucocorticoid receptor
Acute lymphoblastic leukemia
- CpG islands:
Decays per minute
Fetal bovine serum
Food and drug administration
Mitogen-activated protein kinase
Mouse mammary tumor virus
Protein kinase A
Serine 211 of the glucocorticoid receptor
The authors wish to sincerely thank Ms. Betty Johnson of the University of Texas Medical Branch for helpful discussions and editing of the manuscript. Thanks also to Mark Griffin, UTMB Flow Cytometry Core Lab. This study was supported in part by grants (5RO1 CA 41407) from the National Institutes of Health awarded to E. Brad Thompson and (CA 116042) awarded to Wayne V. Vedeckis.
- Fandy TE, Carraway H, Gore SD: DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007, 13 (1): 40-48. 10.1097/PPO.0b013e31803c7359.View ArticlePubMedGoogle Scholar
- Garcia-Manero G, Yang H, Kuang SQ, O’Brien S, Thomas D, Kantarjian H: Epigenetics of acute lymphocytic leukemia. Semin Hematol. 2009, 46 (1): 24-32. 10.1053/j.seminhematol.2008.09.008.View ArticlePubMedGoogle Scholar
- Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006, 5 (1): 37-50. 10.1038/nrd1930.View ArticlePubMedGoogle Scholar
- Xing M: Gene methylation in thyroid tumorigenesis. Endocrinology. 2007, 148 (3): 948-953. 10.1210/en.2006-0927.View ArticlePubMedGoogle Scholar
- Grady WM: Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans. 2005, 33 (Pt 4): 684-688.View ArticlePubMedGoogle Scholar
- Karpf AR: Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr Opin Mol Ther. 2007, 9 (3): 231-241.PubMedGoogle Scholar
- Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM: Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci. 2007, 12: 4254-4266. 10.2741/2385.View ArticlePubMedGoogle Scholar
- Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH: Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res. 2003, 27 (11): 999-1007. 10.1016/S0145-2126(03)00068-7.View ArticlePubMedGoogle Scholar
- Berger J, Daxenbichler G: DNA methylation of nuclear receptor genes–possible role in malignancy. J Steroid Biochem Mol Biol. 2002, 80 (1): 1-11. 10.1016/S0960-0760(01)00179-0.View ArticlePubMedGoogle Scholar
- Leader JE, Wang C, Fu M, Pestell RG: Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol. 2006, 72 (11): 1589-1596. 10.1016/j.bcp.2006.05.024.View ArticlePubMedGoogle Scholar
- Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA: ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 2006, 28 (5–6): 259-272.PubMedGoogle Scholar
- Zhu WG, Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti Canc Agents. 2003, 3 (3): 187-199. 10.2174/1568011033482440.View ArticleGoogle Scholar
- Estey E: Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol Off J Am Soc Clin Oncol. 2007, 25 (14): 1908-1915. 10.1200/JCO.2006.10.2731.View ArticleGoogle Scholar
- Herold MJ, McPherson KG, Reichardt HM: Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006, 63 (1): 60-72. 10.1007/s00018-005-5390-y.View ArticlePubMed CentralPubMedGoogle Scholar
- Ji Z, Mei FC, Johnson BH, Thompson EB, Cheng X: Protein kinase A, not Epac, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells. J Biol Chem. 2007, 282 (52): 37370-37377. 10.1074/jbc.M703697200.View ArticlePubMedGoogle Scholar
- Ji Z, Mei FC, Miller AL, Thompson EB, Cheng X: Protein kinase A (PKA) isoform RIIbeta mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells. J Biol Chem. 2008, 283 (32): 21920-21925. 10.1074/jbc.M803193200.View ArticlePubMed CentralPubMedGoogle Scholar
- Miller AL, Garza AS, Johnson BH, Thompson EB: Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int. 2007, 7: 3-10.1186/1475-2867-7-3.View ArticlePubMed CentralPubMedGoogle Scholar
- Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB: p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol. 2005, 19 (6): 1569-1583. 10.1210/me.2004-0528.View ArticlePubMedGoogle Scholar
- Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Gottgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Lock RB: Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010, 116 (16): 3013-3022. 10.1182/blood-2010-05-284968.View ArticlePubMedGoogle Scholar
- Bhadri VA, Trahair TN, Lock RB: Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J Paediatr Child Health. 2012, 48 (8): 634-640. 10.1111/j.1440-1754.2011.02212.x.View ArticlePubMedGoogle Scholar
- Lippman M: Clinical implications of glucocorticoid receptors in human leukemia. Am J Physiol. 1982, 243 (2): E103-E108.PubMedGoogle Scholar
- Tissing WJ, Meijerink JP, den Boer ML, Brinkhof B, van Rossum EF, van Wering ER, Koper JW, Sonneveld P, Pieters R: Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2005, 11 (16): 6050-6056. 10.1158/1078-0432.CCR-04-2097.View ArticlePubMedGoogle Scholar
- Gasson JC, Bourgeois S: A new determinant of glucocorticoid sensitivity in lymphoid cell lines. J Cell Biol. 1983, 96 (2): 409-415. 10.1083/jcb.96.2.409.View ArticlePubMedGoogle Scholar
- Gasson JC, Ryden T, Bourgeois S: Role of de novo DNA methylation in the glucocorticoid resistance of a T-lymphoid cell line. Nature. 1983, 302 (5909): 621-623. 10.1038/302621a0.View ArticlePubMedGoogle Scholar
- Thompson EB, Smith JR, Bourgeois S, Harmon JM: Glucocorticoid receptors in human leukemias and related diseases. Klin Wochenschr. 1985, 63 (15): 689-698. 10.1007/BF01733111.View ArticlePubMedGoogle Scholar
- Gailani S, Minowada J, Silvernail P, Nussbaum A, Kaiser N, Rosen F, Shimaoka K: Specific glucocorticoid binding in human hemopoietic cell lines and neoplastic tissue. Cancer Res. 1973, 33 (11): 2653-2657.PubMedGoogle Scholar
- Medh RD, Webb MS, Miller AL, Johnson BH, Fofanov Y, Li T, Wood TG, Luxon BA, Thompson EB: Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003, 81 (6): 543-555. 10.1016/S0888-7543(03)00045-4.View ArticlePubMed CentralPubMedGoogle Scholar
- Woodcock DM, Crowther PJ, Simmons DL, Cooper IA: Levels and stability of DNA methylation in random surviving cell clones derived from a Chinese hamster cell line after prolonged treatment with 5-aza-2′-deoxycytidine. Exp Cell Res. 1986, 162 (1): 23-32. 10.1016/0014-4827(86)90423-4.View ArticlePubMedGoogle Scholar
- Hagemann S, Heil O, Lyko F, Brueckner B: Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011, 6 (3): e17388-10.1371/journal.pone.0017388.View ArticlePubMed CentralPubMedGoogle Scholar
- Harmon JM, Norman MR, Fowlkes BJ, Thompson EB: Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line. J Cell Physiol. 1979, 98 (2): 267-278. 10.1002/jcp.1040980203.View ArticlePubMedGoogle Scholar
- Cowan KJ, Storey KB: Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol. 2003, 206 (Pt 7): 1107-1115.View ArticlePubMedGoogle Scholar
- Garza AS, Miller AL, Johnson BH, Thompson EB: Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions. Leuk Res. 2009, 33 (5): 717-727. 10.1016/j.leukres.2008.10.006.View ArticlePubMedGoogle Scholar
- Wang Z, Frederick J, Garabedian MJ: Deciphering the phosphorylation “code” of the glucocorticoid receptor in vivo. J Biol Chem. 2002, 277 (29): 26573-26580. 10.1074/jbc.M110530200.View ArticlePubMedGoogle Scholar
- Ramdas J, Liu W, Harmon JM: Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res. 1999, 59 (6): 1378-1385.PubMedGoogle Scholar
- Geng CD, Schwartz JR, Vedeckis WV: A conserved molecular mechanism is responsible for the auto-up-regulation of glucocorticoid receptor gene promoters. Mol Endocrinol. 2008, 22 (12): 2624-2642. 10.1210/me.2008-0157.View ArticlePubMed CentralPubMedGoogle Scholar
- Zong J, Ashraf J, Thompson EB: The promoter and first, untranslated exon of the human glucocorticoid receptor gene are GC rich but lack consensus glucocorticoid receptor element sites. Mol Cell Biol. 1990, 10 (10): 5580-5585.View ArticlePubMed CentralPubMedGoogle Scholar
- Geng CD, Vedeckis WV: c-Myb and members of the c-Ets family of transcription factors act as molecular switches to mediate opposite steroid regulation of the human glucocorticoid receptor 1A promoter. J Biol Chem. 2005, 280 (52): 43264-43271. 10.1074/jbc.M508245200.View ArticlePubMedGoogle Scholar
- Sarvaiya PJ, Schwartz JR, Hernandez CP, Rodriguez PC, Vedeckis WV: Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol. 2012, 87 (10): 969-976. 10.1002/ajh.23283.View ArticlePubMed CentralPubMedGoogle Scholar
- Sarvaiya PJ, Schwartz JR, Geng CD, Vedeckis WV: c-Myb interacts with the glucocorticoid receptor and regulates its level in pre-B-acute lymphoblastic leukemia cells. Mol Cell Endocrinol. 2012, 361 (1–2): 124-132.View ArticlePubMed CentralPubMedGoogle Scholar
- Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26 (4): 239-257. 10.1038/bjc.1972.33.View ArticlePubMed CentralPubMedGoogle Scholar
- Kerr JF: History of the events leading to the formulation of the apoptosis concept. Toxicology. 2002, 181–182: 471-474.View ArticlePubMedGoogle Scholar
- Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El D, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM: Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009, 16 (8): 1093-1107. 10.1038/cdd.2009.44.View ArticlePubMed CentralPubMedGoogle Scholar
- Achachi A, Florins A, Gillet N, Debacq C, Urbain P, Foutsop GM, Vandermeers F, Jasik A, Reichert M, Kerkhofs P, Lagneaux L, Burny A, Kettmann R, Willems L: Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A. 2005, 102 (29): 10309-10314. 10.1073/pnas.0504248102.View ArticlePubMed CentralPubMedGoogle Scholar
- Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M: Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011, 3 (5): 581-609. 10.2217/epi.11.73.View ArticlePubMedGoogle Scholar
- Oki Y, Issa JP: Epigenetic mechanisms in AML - a target for therapy. Cancer Treat Res. 2010, 145: 19-40.View ArticlePubMedGoogle Scholar
- Tamm I, Wagner M, Schmelz K: Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol. 2005, 84 (Suppl 1): 47-53.View ArticlePubMedGoogle Scholar
- Hsi LC, Xi X, Wu Y, Lippman SM: The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Mol Cancer Ther. 2005, 4 (11): 1740-1746. 10.1158/1535-7163.MCT-05-0218.View ArticlePubMedGoogle Scholar
- Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ: The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011, 118 (10): 2830-2839. 10.1182/blood-2010-07-294827.View ArticlePubMedGoogle Scholar
- Tan PT, Wei AH: The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. Pathology. 2011, 43 (6): 536-546.PubMedGoogle Scholar
- Vannucchi AM, Guglielmelli P, Rambaldi A, Bogani C, Barbui T: Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med. 2009, 13 (8A): 1437-1450. 10.1111/j.1582-4934.2009.00827.x.View ArticlePubMed CentralPubMedGoogle Scholar
- Issa JP, Kantarjian HM: Targeting DNA methylation. Clin Cancer Res. 2009, 15 (12): 3938-3946. 10.1158/1078-0432.CCR-08-2783.View ArticlePubMed CentralPubMedGoogle Scholar
- Geng CD, Vedeckis WV: A new, lineage specific, autoup-regulation mechanism for human glucocorticoid receptor gene expression in 697 pre-B-acute lymphoblastic leukemia cells. Mol Endocrinol. 2011, 25 (1): 44-57. 10.1210/me.2010-0249.View ArticlePubMed CentralPubMedGoogle Scholar
- Miller AL, Johnson BH, Medh RD, Townsend CM, Thompson EB: Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells. Neoplasia. 2002, 4 (1): 68-81. 10.1038/sj.neo.7900208.View ArticlePubMed CentralPubMedGoogle Scholar
- Kaspers GJ, Pieters R, Klumper E, De Waal FC, Veerman AJ: Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma. 1994, 13 (3–4): 187-201.View ArticlePubMedGoogle Scholar
- Tanaka H, Makino Y, Okamoto K, Iida T, Yan K, Yoshikawa N: Redox regulation of the glucocorticoid receptor. Antioxid Redox Signal. 1999, 1 (4): 403-423. 10.1089/ars.1999.1.4-403.View ArticlePubMedGoogle Scholar
- Medh RD, Wang A, Zhou F, Thompson EB: Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene. 2001, 20 (34): 4629-4639. 10.1038/sj.onc.1204680.View ArticlePubMed CentralPubMedGoogle Scholar
- Yuh YS, Thompson EB: Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. Specific c-myc mRNA suppression by dexamethasone. J Biol Chem. 1989, 264 (18): 10904-10910.PubMedGoogle Scholar
- Thompson EB: Stepping stones in the path of glucocorticoid-driven apoptosis of lymphoid cells. Acta Biochim Biophys Sin. 2008, 40 (7): 595-600. 10.1111/j.1745-7270.2008.00433.x.View ArticlePubMedGoogle Scholar
- Pogribny I, Yi P, James SJ: A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun. 1999, 262 (3): 624-628. 10.1006/bbrc.1999.1187.View ArticlePubMedGoogle Scholar
- Golovko G, Khanipov K, Rojas M, Martinez-Alcantara A, Howard JJ, Ballesteros E, Gupta S, Widger W, Fofanov Y: Slim-filter: an interactive Windows-based application for illumina genome analyzer data assessment and manipulation. BMC Bioinforma. 2012, 13: 166-10.1186/1471-2105-13-166.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.